For the past three years, biotechs and pharmas have renamed, rebranded and more in a bid to refresh their corporate appeal. ...
Healx will use its AI-based drug discovery tech to analyze proprietary Sanofi compound data and identify potential rare disease targets.
DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline multiple ...
Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...
MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...
Further boosting the pipeline, mid-stage drugs like Sanofi/Regeneron’s itepekimab, AstraZeneca’s benralizumab, Amgen Inc ...
DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...
The program taps into several OpenAI models and can be used across a wide range of therapeutic indications. Both Big Pharma ...
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in ...
Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...
A treatment of acute myeloid leukemia being developed by Sanofi (SNY) US Services was granted FDA orphan designation, according to a post to the agency’s website. Published first on TheFly – the ...